German specialty chemicals and pharmaceuticals company Merck sees “larger-scale acquisitions” as an option from 2023 onwards as it aims to achieve sales of EUR25bn/year by 2025, said the company.
“As of 2023, Merck will once again consider potential larger-scale acquisitions as an option,” CEO Belen Garijo told investors at the company’s “Capital Markets Day” on Thursday. Merck is targeting three key areas for potential acquisitions: Process Solutions and Life Science Services; Healthcare products; and Semiconductor Solutions.
In August, Merck agreed to acquire the electronic chemicals business of Mecaro, a South Korean supplier to the semiconductor industry. “The current turbulent environment continues to be a stress test for our business model and strategy,” Garijo said.
“I can say with confidence that our highly resilient business sectors are the foundation for our bold plans to accelerate efficient growth and seize organic and inorganic opportunities,” she said. “We remain fully on track to reach our mid-term growth target of €25bn in sales by 2025,” she added.
We remind, Merck, a leading science and technology company, today commissioned its first fully automated unit for the digital color measurement of its pigment products. The unit was commissioned in Gernsheim, Germany, the company’s largest pigments production site. Approximately 560 people work at the site.
mrchub.com